Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer

PURPOSE: To investigate the efficacy and safety of doublet versus single-agent chemotherapy (CT) plus trastuzumab (H) as first-line therapy for human epidermal growth factor 2 receptor (HER2)-positive metastatic breast cancer (MBC). METHODS: We searched for randomized clinical trials (RCTs) that eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Y. F., Wang, Y., Fu, T. P., Chen, K., Liu, J. Q., Yao, H. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838135/
https://www.ncbi.nlm.nih.gov/pubmed/29188398
http://dx.doi.org/10.1007/s10549-017-4592-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838135/
https://www.ncbi.nlm.nih.gov/pubmed/29188398
http://dx.doi.org/10.1007/s10549-017-4592-y

Ejemplares similares